Drug Type Trispecific T-cell engager (TriTE) |
Synonyms HY 0005, HY0005, HY05350 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MSLN inhibitors(Mesothelin inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mesothelin positive Solid Tumors | Phase 2 | China | 03 Jul 2025 | |
Advanced Malignant Solid Neoplasm | IND Approval | China | 01 Jul 2025 | |
Solid tumor | Preclinical | European Union | 18 Oct 2021 |